Inflammatory bowel diseases

GLP-1 receptor agonist treatment is linked to higher symptom remission in ulcerative colitis

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

Ulcerative colitis (UC) is associated with significant morbidity.

  • Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may impact UC disease activity.
  • The effects of GLP-1 RAs on UC remain unclear.
  • Further research is needed to define the relationship between GLP-1 RAs and UC.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Related papers

May '26
IBD outcomes in obese patients treated with GLP-1 drugs versus weight-loss surgery
top 20% journal
cited by 1 paper
journal article
Mar '26
The link between a diabetes medication and rheumatoid arthritis in a large population study
top 10% journal
journal article
Sep '25
Obesity Treatment Comparing Weight-Loss Surgery and GLP-1 Hormone Medicines
top 2% journal
cited by 39 papers
comparative study
Apr '26
Symptom remission in ulcerative colitis linked to semaglutide treatment
case reports
Jun '26
Risk of Gallstones and Bile Duct Problems with Blood Sugar Drugs in Type 2 Diabetes
top 5% journal
journal article
Jun '25
Using a glucagon-like peptide-1 receptor drug before spinal surgery is linked to shorter hospital stays after surgery
top 20% journal
cited by 4 papers
journal article
Apr '26
Changes in Body Fat and Metabolic Risk in Obese Teens Taking GLP-1 Medication
top 30% journal
journal article
Jul '26
Real-world weight loss with different GLP-1 medicines in the All of Us study
top 20% journal
comparative study
Dec '25
Results of GLP-1 Therapy in Obese Ulcerative Colitis Patients with Pouch Surgery and Past Pouch Inflammation
top 10% journal
journal article
Jan '26
Use of GLP-1 Receptor Drugs and Surgery Outcomes After Neck Spine Fusion
top 5% journal
cited by 1 paper
journal article

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #54
GLP-1 drugs don't build habits — and that gap is costing patients their results
5 days ago7 studies
issue #53
Semaglutide slowed aging and extended lifespan in older female mice
1 week ago7 studies
issue #52
GLP-1 drugs linked to lower Parkinson's risk in people with type 2 diabetes
2 weeks ago7 studies
issue #51
Semaglutide linked to nearly double the risk of a rare eye condition in people with diabetes
3 weeks ago7 studies
issue #50
A once-daily pill beat placebo on weight loss — and it wasn't semaglutide
4 weeks ago7 studies
issue #49
GLP-1 drugs work even without weight loss — and scientists are finally mapping why
5 weeks ago7 studies
issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
6 weeks ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
7 weeks ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
8 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief